Response to: 'Comment on: 'How to defuse a demographic time bomb: the way forward?' by Buchan, John C et al.
We thank Prof Claoué for his letter regarding Immediate Sequential Bilateral Cataract Surgery 
(ISBCS).  
Given the increasing mismatch between resources and demand, the national need to move to more 
efficient working practices has to be an inclusive, incremental, collective effort. By advocating a leap 
to a two-visit bilateral cataract pathway or any other unconventional efficiency measure, we would 
be concerned that we might lose the ear of the majority of departments whose pathway currently 
involves five visits for bilateral cataracts. 
The October 2017 NICE guidelines [NG77] on adult cataract surgery recommend us to “Consider 
bilateral simultaneous cataract surgery for people who are at low risk of complications during and 
after surgery”. Whilst there was enough evidence to permit NICE to come to this conclusion, a 
recent systematic review and meta-analysis of ISBCS described the quality of evidence for this 
procedure as “low to very-low”1, and the very fact that ISBCS has been repeatedly proposed as a safe 
practice for over three decades2,3 but has gained little traction in the UK suggests that more work is 
needed to convince those providing cataract surgery to routinely offer ISBCS. 
Prof Claoue expresses the belief that there is little risk from ISBCS, however, intuitively ophthalmic 
surgeons find this hard to comprehend;4 the very low risk of bilateral endophthalmitis 
notwithstanding, consideration might be given to the risk of bilateral cystoid macular oedema 
(CMO). Even excluding patients with risk factors the rate of clinical CMO in the largest study in the 
UK to date with 35563 low risk eyes was 1.17%,5 and first eye CMO is strongly predictive of second 
eye CMO with genetic factors at play,6 a risk that may not be amenable to reduction by topical 
NSAIDs in these low risk eyes.7 
The key to promoting ISBCS nationally is unlikely to lie in convincing surgeons that there is a lack of 
risk. The opportunity to save money for the NHS is also a poor motivator. Rather, we should purpose 
to demonstrate that there is the possibility of doing good to potentially tens of thousands of patients 
annually by providing faster visual rehabilitation and better quality of life through ISBCS. Evidence of 
improved quality of life would perhaps be more convincing to ophthalmologists, but would require a 
large national randomised controlled trial. 
Thus convinced, surgeons would be able to enter into an honest and informed process of shared 
decision making with patients – some of whom will doubtless be delighted with the potential 
benefits of ISBCS, and some of whom will doubtless be wary of the potential risks, small as they are.  
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